Abstract

GARCIA-ARIAS, Mario Ramón et al. Cardiometabolic effect of inhibitors of sodium glucose cotransporter type 2 (SGLT2). Med. interna Méx. [online]. 2018, vol.34, n.6, pp.924-932. ISSN 0186-4866.  https://doi.org/10.24245/mim.v34i6.2140.

There is an increase in the use of new drugs for the treatment of the different elements that integrate the metabolic syndrome; that, by their pharmacokinetics and pharmacodynamics have a pleiotropic effect. Recently, the inhibitors of sodium glucose cotransporter type 2 (SGLT2) used for the treatment of diabetes mellitus type 2 have demonstrated a cardio-renal protector effect. They function at the S1 segment of the proximal tube, lowering the filtration of glucose and enhancing its excretion; resulting in a glycosuric and natriuretic effect. This is the main mechanism of cardiovascular protection. Experimental essays and different studies, such as the EMAREG study and the CANVAS program, have established that the inhibitors of SGLT2 reduce the progression of hypertrophic cardiomyopathy, fibrosis, cardiac remodeling, systolic dysfunction and heart failure. The results of these studies recognize this group of drugs (empaglifozine and canaglifozine) as a valid treatment for cardiovascular protection in patients with diabetes mellitus type 2, and which is recommended by the FDA, the ACC/AHA, the European Society of Cardiology and the American Diabetes Association (ADA) in its last publication in 2018.

Keywords : Inhibitors of sodium glucose cotransporter type 2; Diabetes mellitus type 2; Cardiovascular diseases.